Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

in response to

Re: Celgene inks $1B deal for a preclinical epigenetic blood cancer drug from Canada.

Nextblockbuster

posted on Jan 30, 2019 10:04AM

NBB - My understanding is that the current trial has already morphed into a Phase II trial.